Advances in the Medical Treatment of Diabetic Retinopathy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (20 May 2022) | Viewed by 2700
Special Issue Editor
Interests: diabetic complications; technological advances in diabetes care
Special Issue Information
Dear Colleagues,
Diabetic retinopathy is a prevalent diabetic complication with important social and budgetary repercussions. Treatments such as intravitreal injections and laser photocoagulation are focused on the late stages of the disease, but there is no specific treatment for the early stages. Moreover, in advanced retinal disease, when a diabetic macular edema is present, the response to intravitreal injections, which are invasive, is heterogeneous, and more personalized medicine is needed. New approaches and new therapeutic targets, as well as new drug delivery forms in diabetic retinopathy treatment, have arisen in recent years.
The aim of this Special Issue of Pharmaceutics is to compile high-quality papers related to the medical treatment of diabetic retinopathy (clinical or experimental), with especial emphasis on the early stages of the disease. Papers (review articles or original research) focusing on new therapeutic targets, new drug delivery forms or a personalized management of diabetic retinopathy will be welcome in this Special Issue.
Dr. Olga Simó-Servat
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetic retinopathy
- diabetic macular edema
- neurovascular unit
- treatment of diabetics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
